Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 7/20 | 0.47 |
| ▸ | NPY4R | P50391 | 7/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.47 |
| ▸ | NPY1R | P25929 | 5/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867735 | 0.87 | CALCR (0.49) | CALCRHCRTR1HCRTR2KEAP1NPY2R | |
| SCHEMBL30712934 | 0.86 | CALCR (0.62) | CALCRHCRTR1HCRTR2CXCR4MAPK8 | |
| SCHEMBL30567784 | 0.85 | NPY2R (0.61) | CALCRCXCR4MAPK8MAPK9MAPK10 | |
| SCHEMBL30574975 | 0.85 | MAPK8 (0.47) | CALCRHCRTR1HCRTR2KEAP1MAPK8 | |
| SCHEMBL29390993 | 0.85 | F2 (0.51) | CALCRCXCR4NPY2RNPY4RNPY5R | |
| SCHEMBL31138107 | 0.84 | MAPK8 (0.55) | CALCRCXCR4MAPK8MAPK9MAPK10 | |
| SCHEMBL31507665 | 0.84 | CALCR (0.63) | CALCRCXCR4NPY2RNPY4RNPY5R | |
| SCHEMBL30432355 | 0.84 | CALCR (0.65) | CALCRHCRTR1HCRTR2NPY2RNPY4R | |
| SCHEMBL30432890 | 0.84 | NPY2R (0.53) | CALCRHCRTR1HCRTR2KEAP1MAPK8 | |
| SCHEMBL31295727 | 0.83 | CALCR (0.60) | CALCRHCRTR1HCRTR2CXCR4NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | CALCR 3315/4885HCRTR1 2281/4885HCRTR2 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.